137 related articles for article (PubMed ID: 18022979)
21. Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.
Tagad HD; Debnath S; Clausse V; Saha M; Mazur SJ; Appella E; Appella DH
ChemMedChem; 2018 May; 13(9):894-901. PubMed ID: 29476592
[TBL] [Abstract][Full Text] [Related]
22. Diphenylpyrroles: Novel p53 activators.
Gomha SM; Eldebss TM; Abdulla MM; Mayhoub AS
Eur J Med Chem; 2014 Jul; 82():472-9. PubMed ID: 24934571
[TBL] [Abstract][Full Text] [Related]
23. Wip1 phosphatase deficiency impairs spatial learning and memory.
Liu SC; Zhang M; Gan P; Yu HF; Ding CF; Zhang RP; He ZY; Hu WY
Biochem Biophys Res Commun; 2020 Dec; 533(4):1309-1314. PubMed ID: 33051059
[TBL] [Abstract][Full Text] [Related]
24. Wip1 phosphatase: between p53 and MAPK kinases pathways.
Goloudina AR; Kochetkova EY; Pospelova TV; Demidov ON
Oncotarget; 2016 May; 7(21):31563-71. PubMed ID: 26883196
[TBL] [Abstract][Full Text] [Related]
25. Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphorylation states.
Zhang YY; Mei ZQ; Wu JW; Wang ZX
J Biol Chem; 2008 Sep; 283(39):26591-601. PubMed ID: 18669639
[TBL] [Abstract][Full Text] [Related]
26. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1.
Hershko T; Korotayev K; Polager S; Ginsberg D
J Biol Chem; 2006 Oct; 281(42):31309-16. PubMed ID: 16912047
[TBL] [Abstract][Full Text] [Related]
27. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
28. Wip1-dependent signaling pathways in health and diseases.
Zhu YH; Bulavin DV
Prog Mol Biol Transl Sci; 2012; 106():307-25. PubMed ID: 22340722
[TBL] [Abstract][Full Text] [Related]
29. The Regulation of Trophoblastic p53 Homeostasis by the p38-Wip1 Feedback Loop is Disturbed in Placentas from Pregnancies Complicated by Preeclampsia.
Tan B; Tong C; Yuan Y; Xu P; Wen L; Zhang C; Zheng Y; Lin L; Zhu F; Gui S; Wang L; Gao R; Li J; Qi H; Baker PN
Cell Physiol Biochem; 2019; 52(2):315-335. PubMed ID: 30816677
[TBL] [Abstract][Full Text] [Related]
30. Probing protein phosphatase substrate binding: affinity pull-down of ILKAP phosphatase 2C with phosphopeptides.
Højlys-Larsen KB; Sørensen KK; Jensen KJ; Gammeltoft S
Mol Biosyst; 2012 Apr; 8(5):1452-60. PubMed ID: 22348942
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Ogasawara S; Kiyota Y; Chuman Y; Kowata A; Yoshimura F; Tanino K; Kamada R; Sakaguchi K
Bioorg Med Chem; 2015 Oct; 23(19):6246-9. PubMed ID: 26358280
[TBL] [Abstract][Full Text] [Related]
32. Potent, orally absorbed glucagon receptor antagonists.
de Laszlo SE; Hacker C; Li B; Kim D; MacCoss M; Mantlo N; Pivnichny JV; Colwell L; Koch GE; Cascieri MA; Hagmann WK
Bioorg Med Chem Lett; 1999 Mar; 9(5):641-6. PubMed ID: 10201821
[TBL] [Abstract][Full Text] [Related]
33. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
34. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
Hayashi R; Tanoue K; Durell SR; Chatterjee DK; Jenkins LM; Appella DH; Appella E
Biochemistry; 2011 May; 50(21):4537-49. PubMed ID: 21528848
[TBL] [Abstract][Full Text] [Related]
35. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
36. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells.
Franklin CC; Kraft AS
J Biol Chem; 1997 Jul; 272(27):16917-23. PubMed ID: 9202001
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Seo H; Cho S
Pharmazie; 2016 Apr; 71(4):196-200. PubMed ID: 27209699
[TBL] [Abstract][Full Text] [Related]
38. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.
Yoda A; Xu XZ; Onishi N; Toyoshima K; Fujimoto H; Kato N; Oishi I; Kondo T; Minami Y
J Biol Chem; 2006 Aug; 281(34):24847-62. PubMed ID: 16798742
[TBL] [Abstract][Full Text] [Related]
40. Phosphatase Wip1 negatively regulates neutrophil development through p38 MAPK-STAT1.
Liu G; Hu X; Sun B; Yang T; Shi J; Zhang L; Zhao Y
Blood; 2013 Jan; 121(3):519-29. PubMed ID: 23212517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
